Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TLPH
stocks logo

TLPH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.070
-0%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Talphera, Inc. (TLPH) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 129.42%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.17%
In Past 3 Month
Stock Price
Go Up
up Image
+129.42%
In Past 3 Month
Wall Street analysts forecast TLPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLPH is 3.25 USD with a low forecast of 3.00 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast TLPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLPH is 3.25 USD with a low forecast of 3.00 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.260
sliders
Low
3.00
Averages
3.25
High
3.50
Current: 1.260
sliders
Low
3.00
Averages
3.25
High
3.50
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$6
2025-04-01
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$6
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$6
2025-01-21
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$6
2025-01-21
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Talphera Inc (TLPH.O) is -4.73, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess Talphera Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.08
Current PE
-4.73
Overvalued PE
0.55
Undervalued PE
-4.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.58
Undervalued EV/EBITDA
-4.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
363.65
Current PS
0.00
Overvalued PS
1924.71
Undervalued PS
-1197.41
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 3806.25% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 3806.25% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TLPH News & Events

Events Timeline

(ET)
2025-11-12
16:15:48
Talphera announces Q3 earnings per share of 11 cents, compared to a loss of 13 cents in the same period last year.
select
2025-10-28 (ET)
2025-10-28
16:31:49
Talphera Seeks Approval to Sell 1.02 Million Shares of Common Stock for Shareholders
select
2025-09-22 (ET)
2025-09-22
17:13:15
Talphera Seeks Approval to Sell 25.04 Million Shares of Common Stock for Shareholders
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-13PRnewswire
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

  • Financing Update: Talphera, Inc. closed a $17 million first tranche financing led by CorMedix, Inc., with expectations of sufficient capital through a potential PMA approval of their product Niyad in late 2026.

  • Clinical Study Progress: Five out of nine target clinical sites for the NEPHRO study are activated, with completion expected in the first half of 2026, and positive enrollment momentum reported.

  • Financial Performance: For Q3 2025, Talphera reported a net loss of $4.4 million, slightly higher than the previous year, with cash and investments totaling $21.3 million as of September 30, 2025.

  • Future Guidance: The company anticipates cash operating expenses for 2025 to be between $14 million and $15 million, a reduction from previous estimates, as they continue to advance the NEPHRO CRRT registration trial.

[object Object]
Preview
9.5
11-06PRnewswire
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025

  • Financial Results Announcement: Talphera, Inc. will release its third quarter 2025 financial results on November 12, 2025, followed by a live webcast and conference call at 4:30 p.m. ET to discuss the results and business updates.

  • Webcast and Conference Call Details: The webcast can be accessed through Talphera's website, and a replay will be available for 90 days. Investors can join the conference call using specific dial-in numbers and a conference ID.

  • Company Overview: Talphera, Inc. is a specialty pharmaceutical company focused on developing innovative therapies for medically supervised settings, with its lead product candidate, Niyad™, currently under investigation as an anticoagulant.

  • Regulatory Status: Niyad™ has received Breakthrough Device Designation from the FDA, highlighting its potential significance in medical applications.

[object Object]
Preview
8.5
10-09NASDAQ.COM
Post-Market Jump: Turn Therapeutics Soars 134% Following Nasdaq Debut; Biotech Stocks Rise

  • Surge in Biotech Stocks: U.S.-listed biotech and healthcare stocks experienced significant after-hours gains, with Turn Therapeutics Inc. leading the way, surging 134.29% after its Nasdaq debut.

  • Momentum and Anticipation: Other companies like Talphera Inc. and Ionis Pharmaceuticals Inc. also saw notable increases, driven by momentum and upcoming presentations, indicating a strong interest in the biotech sector.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Talphera Inc (TLPH) stock price today?

The current price of TLPH is 1.26 USD — it has decreased -3.08 % in the last trading day.

arrow icon

What is Talphera Inc (TLPH)'s business?

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

arrow icon

What is the price predicton of TLPH Stock?

Wall Street analysts forecast TLPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLPH is 3.25 USD with a low forecast of 3.00 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Talphera Inc (TLPH)'s revenue for the last quarter?

Talphera Inc revenue for the last quarter amounts to 1,000 USD, decreased % YoY.

arrow icon

What is Talphera Inc (TLPH)'s earnings per share (EPS) for the last quarter?

Talphera Inc. EPS for the last quarter amounts to -0.11 USD, decreased -15.38 % YoY.

arrow icon

What changes have occurred in the market's expectations for Talphera Inc (TLPH)'s fundamentals?

The market is revising No Change the revenue expectations for Talphera, Inc. (TLPH) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 129.42%.
arrow icon

How many employees does Talphera Inc (TLPH). have?

Talphera Inc (TLPH) has 13 emplpoyees as of December 05 2025.

arrow icon

What is Talphera Inc (TLPH) market cap?

Today TLPH has the market capitalization of 58.73M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free